Parkinson Disease Protein 2 Human Recombinant

PARK2 is an element in a multiprotein E3 ubiquitin ligase complex which mediates the targeting of substrate proteins for proteasomal degradation. PARK2 alterations can result in Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing creates multiple transcript variants encoding distinct isoforms.

Description: PARK2 Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 485 amino acids (1-465) and having a molecular mass of 53.8 kDa. PARK2 is fused to a 20 amino acid His-tag at N-terminus.

Physical Appearance: Sterile Filtered clear solution.

Formulation: The PARK2 solution (1mg/ml) contains 20mM Tris-HCl buffer (pH 8.0), 0.4M Urea and 10% glycerol.

Stability: Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles.